美國Oct4-GFP報告基因小鼠胚胎干細(xì)胞
美國PrimCells干細(xì)胞：PrimCells提供多種報告基因敲進的小鼠胚胎干細(xì)胞，該類細(xì)胞皆在原始基因座上敲入熒光報告基因，從而使熒光蛋白的表達能真實反映原基因座附近的表達調(diào)控狀況。該類細(xì)胞作為研究胚胎干細(xì)胞自更新和定向分化的有力工具，受到多家有名研究所研究人員的青睞。
美國Oct4-GFP報告基因小鼠胚胎干細(xì)胞
Oct4 is a transcriptional factor from POU protein family. It is one of the most important markers for undifferentiated embryonic stem cells and is required to maintain the self-renwal of mESCs1. Oct4 is also associated with human germ cell tumors2.
PrimCells is proud to isolate and provide to the research community the culture of Oct4-EGFP ESCs from transgenic knock-in mice. These cells were cultured in standard ESCs medium on gelatin coated plates and be used as a powerful tool to examine the mechanism of self-renwal of mouse embryonic stem cells. Oct4-GFP mESCs should be maintained in the stem cell culture medium with LIF to maintain the pluripotent state (Figure 1).
Note: This cell line is puromycin-resistent.
Figure 1. Oct4-GFP mESCs show GFP signals when maintained in ESC medium (Left). The differentiated cells lose the GFP signals in the absence of LIF (Right).
References
1. Loh, Y.H. et al. The Oct4 and Nanog transcription network regulates pluripotency in mouse embryonic stem cells. Nat Genet 38, 431-440 (2006).
2. Looijenga, L.H. et al. POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res 63, 2244-2250 (2003).
美國PrimCells品牌介紹
PrimCells是位于美國加州圣迭戈的一家專業(yè)致力于細(xì)胞產(chǎn)品研發(fā)和解決方案提供的業(yè)內(nèi)技術(shù)領(lǐng)導(dǎo)企業(yè)。
公司匯集了**的生物醫(yī)藥技術(shù)專家，獨立開發(fā)了多項原代細(xì)胞和干細(xì)胞相關(guān)的專有技術(shù)。 公司以“細(xì)胞研究的選擇”為宗旨，自主研發(fā)超過70種**產(chǎn)品，填補了多個特種細(xì)胞市場的空白。例如其誘導(dǎo)性表達細(xì)胞庫和高效3D皮膚培養(yǎng)系統(tǒng)，皆為該類產(chǎn)品目前市場上少數(shù)的規(guī)模化供應(yīng)商。此外，公司以高質(zhì)量的數(shù)據(jù)與快速穩(wěn)定的項目完成時間，長期為多家知名制藥公司提供解決方案，獲得用戶廣泛贊譽。
PrimCells產(chǎn)品線：
1. 報告基因干細(xì)胞 2. 原代細(xì)胞（含報告基因原代細(xì)胞） 3. 誘導(dǎo)性穩(wěn)定細(xì)胞株
4. 人源重組蛋白 5. **型培養(yǎng)試劑
PrimCells 解決方案
1.誘導(dǎo)性穩(wěn)定細(xì)胞株開發(fā) 2. 原代細(xì)胞開發(fā) 3. **體外毒理和效能測試 4. 3D-皮膚培養(yǎng)
PrimCells合作伙伴及客戶:
A．生物制藥公司：輝瑞(Pfizer), 諾華(Novartis), 禮來(Eli2 Lilly),. Amgen, EMD Millipore, Regeneron等公司的毒理和醫(yī)藥研發(fā)部門
B．科研機構(gòu)：冷泉港實驗室，哈佛醫(yī)學(xué)院, 麻省理工（MIT）,， UCSF, NYU, Salk, UIUC, USC等
